| Property | Value |
|---|
|
?:abstract
|
-
BACKGROUND Tetracyclines (TetraC) are widely used in dermatology for both inflammatory and infectious dermatoses; recently both in vivo and in vitro studies started to suggest also a potential anti-viral effect. During COVID-19 outbreak, several dermatological patients contracted SARS-CoV-2 experiencing only mild symptoms, but no protocol were approved. METHODS We performed a multicenter prospective observational study that enrolled COVID-19 patients visited with teledermatology and undergoing TetraC. RESULTS We enrolled 38 adult outpatients (M/F: 20/18, age 42.6 years [21-67]). During the TetraC treatment, symptoms resolved in all patients within 10 days. Remarkably, ageusia and anosmia disappeared in the first week of TetraC treatment. CONCLUSIONS TetraC seem a promising drug to treat COVID-19 outpatients with mild symptoms. This article is protected by copyright. All rights reserved.
|
|
?:creator
|
|
|
?:doi
|
|
|
?:doi
|
|
|
?:journal
|
|
|
?:license
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:source
|
|
|
?:title
|
-
Tetracyclines in COVID-19 patients quarantined at home: Literature evidence supporting Real-World Data from a Multicenter Observational Study Targeting Inflammatory & Infectious Dermatoses.
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}